InvestorsHub Logo
Followers 0
Posts 23
Boards Moderated 0
Alias Born 05/12/2006

Re: None

Saturday, 09/16/2006 10:19:01 AM

Saturday, September 16, 2006 10:19:01 AM

Post# of 346545
Dr. Thorpe "A GROWING BODY of preclinical and CLINICAL data indicates that therapies targeting PS have SIGNIFICANT potential as novel immunotherapeutics to treat cancer and VIRAL infections". Steven King "As our lead anti-PS agent bavituximab advances in CLINICAL STUDIES for the treatment of cancer and hepatitis C infection, we are INCREASINGLY enthusiastic about the clinical potential of its unique mechanism".......and some think the hep C data they are seeing is not good...GET REAL. In this day and age of shareholder lawsuits and CEO's GOING TO JAIL....you really think SK is going to make a statement like that in the face of bad data...NFW!!!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News